A Phase 1, Single Dose, Open-Label Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04634817
Latest Information Update: 05 Mar 2024
Price :
$35 *
At a glance
- Drugs PF 4634817 (Primary)
- Indications Diabetic nephropathies
- Focus Pharmacokinetics
- 16 Sep 2013 Planned end date changed from 1 Jan 2014 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Jun 2013 Planned end date changed from 1 Feb 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.